sglt2 glp 1 combination Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain A retrospective analysis of combination

Learn what researchers discovered, why the findings matter, and key reminders for people with type 2 diabetes concerned about brain health.

Purpose of Review The development of long-acting incretin receptor agonists represents a significant advance in the fight against the concurrent epidemics of type 2 diabetes mellitus (T2DM) and obesity

People working to reduce alcohol harm may feel like celebrating, but we should be wary []

MAGIC FOR YOUR MIND & BODY: Each scoop of Yerba Magic blends yerba mate, lions mane mushroom, prebiotics, and probiotics into one super drink

Improving the plumbing does not repair the degenerating circuitry. These images show thehuman hippocampus, a memory-critical region, in Alzheimers disease: H&E (top left):overall structural collapse, neuronal loss, inflammation

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) represent a cornerstone in the treatment of diabetes and obesity and have emerged as a promising option for other metabolic disorders, including hepatic steatosis